Blanket Purchase Agreement 36F79719D0224-36E79724A0031
Award Date 9/20/24
Last Date to Order 10/29/25
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed Similar IDVs
- Horizon Therapeutics USA, Inc., a global biotechnology company, holds a $25 million Multiple Award Schedule contract with the U.S. Department of Veterans Affairs (VA) for Pharmaceuticals and Drugs (FSS-61-IB), which expires in August 2025. This contract allows the VA's Veterans Health Administration (VHA) and Veterans Integrated Service Networks (VISNs) to place firm fixed-price delivery orders for Horizon's specialty pharmaceuticals, including KRYSTEXXA (pegloticase) used to treat chronic gout....
- This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to Nobelpharma America, LLC, a foreign-owned, self-certified small disadvantaged business. The single-award BPA, valued at up to $4.5 million, is for the delivery of the medication HYFTOR through June 2026. HYFTOR is likely used to treat conditions like post-traumatic stress disorder and chronic pain among veterans. In addition to this BPA, Nobelpharma America, LLC...
- The U.S. Department of Veterans Affairs (VA) National Acquisition Center has awarded a single-award Blanket Purchase Agreement (BPA) to Vifor (International) AG, a Swiss-based pharmaceutical manufacturer, under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The $150,000 BPA, which expires on June 24, 2026, is specifically for the procurement of KORSUVA (difelikefalin), a medication used to treat pruritus. Additionally, Vifor (International) AG holds a separate $23.8 million...
- This single-award Blanket Purchase Agreement, valued at $3.16 million, was awarded by the U.S. Department of Veterans Affairs National Acquisition Center to Recordati Rare Diseases Inc. on July 13, 2021, with a performance period extending through July 12, 2026. The BPA is established under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and contains no set-aside designations. The contract provides the VA with a streamlined procurement mechanism for five specialized...
- Takeda Pharmaceuticals America Inc. has been awarded a single-award Blanket Purchase Agreement by the Department of Veterans Affairs National Acquisition Center valued at $131.04 million with a performance period from July 15, 2025, through July 14, 2026. This indefinite delivery vehicle falls under the General Services Administration Pharmaceuticals and Drugs Schedule (FSS-61-IB) and encompasses procurement of nine specialized pharmaceutical products: CINRYZE, KALBITOR, TAKHZYRO, ELAPRASE,...
- The Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Viela Bio, Inc. for the pharmaceutical Uplizna. With a potential value of $4,348,680, the single award BPA has a period of performance through May 5, 2022 and was awarded on January 12, 2021. The BPA was established against the Pharmaceuticals and Drugs GSA schedule to provide Uplizna, which is indicated for the treatment of neuromyelitis optica spectrum disorder in adult patients...
- The Department of Veterans Affairs (VA) has awarded Xeris Pharmaceuticals, Inc., a small disadvantaged business manufacturer, a multiple award Federal Supply Schedule (FSS) contract under VA Integrated Service Network 12. The contract, valued at up to $4,119,200, allows the VA to procure Xeris' drugs, pharmaceuticals, and hematology products to support healthcare operations from July 2020 to April 2026. Additionally, the VA National Acquisition Center awarded Xeris a single award Blanket...
- This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to United Therapeutics Corporation, a self-certified small disadvantaged business and for-profit manufacturer of pharmaceutical goods. The BPA has a ceiling value of $207,127,385 and a performance period extending through April 2026. It allows the VA to procure specialized pharmaceutical products from United Therapeutics' portfolio, including Orenitram, Remodulin, Tyvaso,...
- The Department of Veterans Affairs awarded a multiple-award Federal Supply Schedule contract to Viela Bio, Inc. against the Pharmaceuticals and Drugs schedule for an estimated $12.98 million. This IDV establishes supply of pharmaceutical products to various VA medical centers nationwide through 2022. A single-award Blanket Purchase Agreement against the same FSS schedule was also awarded to Viela Bio for an estimated $4.35 million. This BPA facilitates streamlined delivery of the neuromyelitis...
- BioMarin Pharmaceutical Inc., a for-profit pharmaceutical manufacturer, was awarded a single-award Blanket Purchase Agreement (BPA) by the Department of Veterans Affairs (VA) under GSA Schedule 61-IB for Pharmaceuticals and Drugs. The $151,685 BPA has a potential value over $3 million and will run through October 2024, facilitating the VA's procurement of the drug Palynziq (pegvaliase-pqpz) to treat phenylketonuria in adult patients. Under this BPA, the VA has issued a $117,376.50 firm...